optiray

OPTIRAY® (Ioversol)

Agility for seamless integration into your

practice

The information displayed on this website is about Optiray® contrast medium. This website is a global information resource intended only for Healthcare Professionals. It contains both educational and promotional materials. The site is not country specific and may vary from the approved product information in the country where you are located. Some products mentioned in this website may not be registered, nor commercially available in all countries. Please contact your local Guerbet representative for further details.

PFS C1 IMAGE ONLY

With its unique combination of ready-to-use presentation, wide range of concentrations, and appropriate physicochemical properties1-4, Optiray® helps you cover a large array of clinical situations, including the challenging ones.1,5,6

Optiray® (ioversol) is a non-ionic monomeric, low osmolar iodinated contrast agent intended for intravascular administration. Depending on the indication, Optiray® can be administered either by intravenous (IV) or intra-arterial route (IA).

Optiray® is supplied in 4 different concentrations: 240, 300, 320 and 350 mg I/mL.*

Optiray® is approved for use in adults and children in a wide range of indications, helping you to cover a large array of clinical situations, including the challenging ones.

It is approved in more than 65 countries.*

Show More

AGILITY for seamless integration into your practice

Optiray® is well-known thanks to its unique combination of ready-to-use presentation (prefilled syringes), wide range of concentrations (including 320mgI/mL, not available among other LOCM) and appropriate physicochemical properties.

Optiray® is commercialized in vials and in prefilled syringes, a solution designed to enhance safety and efficiency in radiology units. Prefilled syringes can bring several benefits to your daily practice helping to prevent microbiologic contamination in clinical routine, especially in the case of immunocompromised patients7 as well as the reduction of crossed infection or patient administration errors8. An extensive list of benefits can be experienced, including an easier manipulation by radiographers9. Optiray in prefilled syringes are available in 50 to 125mL volumes to adapt best to your scanner technology, patient morphology and examination type.*

* Not all the concentrations and indications may be available in your country. Indication may vary from children to adult population Please check with your local Guerbet representative for more information

Optiray® contrast agent has six hydroxyl groups evenly arranged around the tri-iodinated benzene ring and has no methyl group. It possesses properties of high hydrophilicity, low viscosity and is classified as low osmolality contrast media.1-3

The combination of single and multi-use presentations, its appropriate physicochemical properties and its broad range of indications makes Optiray® the agile product that fits in most imaging situations, for diagnostic and interventional procedures.  

 

Learn more on the science of OPTIRAY®.

Complete the form below to receive key information.

Learn more on the science of OPTIRAY®.

Complete the form below to receive the full publication

Diagnostic Imaging Interconnected Solutions

Driven by its commitment to advance radiology, Guerbet Diagnostic Imaging has designed a comprehensive and complete portfolio of products and solutions for diagnostic imaging.

Diagnostic Imaging Solutions For Radiology

Sources and references

1. SmPC

2. Le Mignon MM, Azau C, Arthaud A, Bonnemain B. Preliminary European intravenous clinical experience with a new, low osmolar, nonionic contrast medium: ioversol (Optiray®). Eur J Radiol. 1991;13:126-133.

3. Voeltz MD, et al. The Important Properties of Contrast Media: Focus on Viscosity. J Invasiv Cardiol 2007;19(3):1A-9A.

4. Bonnemain B, et al. New iodinated, low-osmolar contrast media. A revised concept of hydrophilicity. Invest Radiol 1990;25(Suppl 1):S104-6.

5. Azzalini L, et al. Incidence of contrast-induced acute kidney injury in a large cohort of all-comers undergoing percutaneous coronary intervention: Comparison of five contrast media. Int J Cardiol 2018;273:69–73.

6. Iyengar SS, et al. Diagnostic accuracy of high-definition CT coronary angiography in high-risk patients. Clin Radiol 2016;71:151-158.

7. Buerke et al, Microbiologic Contamination and Time Efficiency of Use of Automatic MDCT Injectors with Prefilled Syringes: Results of a Clinical Investigation. AJR 2010; 194:299–303

8. Vogl TJ et al. An observational study to evaluate the efficiency and safety of ioversol pre-filled syringes compared with ioversol bottles in contrast-enhanced examinations. Acta Radiol. 2012: 1-7

9. Pichler W et al. Hygiene-related considerations for examinations conducted with contrast media. Wiener Klinisches Magazin; March 2009:36-39

10. Thomsen HS. Management of acute adverse reactions to contrast media. In: Thomsen HS, editor. Contrast Media: Safety Issues and ESUR Guidelines. Heidelberg, Springer;2006. pp. 19-25

11. Jost G, et al. The Impact of the Viscosity and Osmolality of Iodine Contrast Agents on Renal Elimination. Invest Radiol. 2010;45:255-261.

12. Geenen RW, et al. Contrast-induced nephropathy: pharmacology, pathophysiology and prevention. Insights Imaging. 2013;4:811-820.

Read product information

P21000538 – April 2021